Vaping companies sue to delay U.S. e-cigarette review
A vaping industry group sued the U.S. government Wednesday to delay an upcoming review of thousands of e-cigarettes on the market.
The legal challenge by the Vapor Technology Assn. is the latest hurdle in the Food and Drug Administration’s years-long effort to regulate the multibillion-dollar vaping industry, which includes makers and retailers of e-cigarette devices and flavored solutions.
The vaping group argued that the latest deadline of next May to submit products for review could wipe out many of the smaller companies. The lawsuit was filed in U.S. District Court in Kentucky.
E-cigarettes first appeared in the United States more than a decade ago and have grown in popularity despite little research on their long-term effects, including whether they can help smokers quit cigarettes.
In recent years, health authorities have warned of an epidemic of vaping by underage teenagers, particularly the leading brand, Juul. The San Francisco company — one of the vaping association’s 800 members — is known for its products’ high nicotine content and its easy-to-conceal device, which resembles a flash drive.
Nicotine is what makes both cigarettes and e-cigarettes addictive, and health experts say the chemical is harmful to developing brains.
The 2009 law that gave the FDA power over the traditional tobacco products did not mention e-cigarettes. And it wasn’t until 2016 that the agency expanded its own regulations to include the devices. But since then, FDA regulators have repeatedly pushed back the timeline, at one point until 2022, to begin reviewing the legions of vaping products that have come to market.
Frustrated by the delays, anti-tobacco groups including the Campaign for Tobacco-Free Kids sued the FDA to speed up the process. In June, a federal judge sided with the groups and set a deadline of next May for all companies to submit their products for federal review. The FDA did not appeal the decision.
The vape group’s lawsuit said the FDA has now set five deadlines.
“It is time for FDA to stop moving the goalposts and changing the rules in the middle of the game to the detriment of our manufacturers and small businesses,” Tony Abboud, the group’s executive director, said in a statement.
Vaping executives have long said that most companies will not be able to afford to conduct large, expensive studies needed for FDA review. Only products that meet FDA standards would be permitted to be sold.
The FDA declined to comment on the lawsuit.
Your guide to our new economic reality.
Get our free business newsletter for insights and tips for getting by.
You may occasionally receive promotional content from the Los Angeles Times.